Skye Bioscience, INC. (SKYE) — 8-K Filings

8-K Filings (14)

• 8-K Filing — Dec 23, 2025
• Skye Bioscience Files 8-K — Oct 6, 2025 Risk: low
  Skye Bioscience, Inc. filed an 8-K on October 6, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly know
• Skye Bioscience Files 8-K: Accountant, Shareholder Votes, Exhibits — Jun 11, 2025 Risk: low
  Skye Bioscience, Inc. filed an 8-K on June 11, 2025, reporting on events that occurred on June 6, 2025. The filing indicates changes in the registrant's certify
• Skye Bioscience Files 8-K on Director/Officer Changes — Feb 26, 2025 Risk: low
  Skye Bioscience, Inc. filed an 8-K on February 26, 2025, reporting on the departure of directors, election of directors, appointment of officers, and compensato
• Skye Bioscience Appoints New CMO, Director — Oct 29, 2024 Risk: medium
  Skye Bioscience, Inc. announced on October 28, 2024, the appointment of Dr. Robert L. Smith as Chief Medical Officer and the election of Ms. Sarah Chen to its B
• Skye Bioscience Files 8-K: Director Changes & Officer Compensation — Oct 24, 2024 Risk: medium
  Skye Bioscience, Inc. filed an 8-K on October 24, 2024, reporting on the departure of a director, election of a new director, and a compensatory arrangement for
• Skye Bioscience Appoints New CMO, Adds Directors — Sep 4, 2024 Risk: medium
  Skye Bioscience, Inc. announced on September 3, 2024, the appointment of Dr. Michael J. Mullan as Chief Medical Officer and the election of Dr. Mullan and Ms. S
• Skye Bioscience Appoints New CMO, Adds Directors — Jul 3, 2024 Risk: medium
  Skye Bioscience, Inc. announced on July 1, 2024, the appointment of Dr. Robert L. Smith as Chief Medical Officer and the election of Dr. Smith and Ms. Sarah Che
• Skye Bioscience Files 8-K — Jun 10, 2024 Risk: low
  Skye Bioscience, Inc. filed an 8-K on June 10, 2024, reporting other events and financial statements. The company, formerly known as Emerald Bioscience, Inc. an
• Skye Bioscience Files 8-K — Apr 3, 2024 Risk: low
  Skye Bioscience, Inc. filed an 8-K on April 3, 2024, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known
• Skye Bioscience Files 8-K: Material Agreement & Equity Sales — Mar 13, 2024 Risk: medium
  Skye Bioscience, Inc. announced on March 11, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sales of equi
• Skye Bioscience Appoints New CMO, Elects Director — Mar 4, 2024 Risk: medium
  Skye Bioscience, Inc. announced on February 29, 2024, the appointment of Dr. Michael J. McVicar as Chief Medical Officer and the election of Dr. Robert L. T. Sm
• Skye Bioscience Files 8-K for Corporate Info Update — Feb 12, 2024 Risk: low
  Skye Bioscience, Inc. filed an 8-K on February 12, 2024, to update its corporate information, including its current name and business address at 11250 El Camino
• Skye Bioscience Reports Material Agreement & Unregistered Equity Sales — Jan 29, 2024
  Skye Bioscience, Inc. filed an 8-K on January 29, 2024, reporting an "Entry into a Material Definitive Agreement" and "Unregistered Sales of Equity Securities."

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX